Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Richard_L._Mulligan
|
| gptkbp:focusesOn |
oncology
pharmaceuticals |
| gptkbp:founded |
1981
|
| gptkbp:hasCompany |
true
|
| gptkbp:hasPatent |
PEGylation technology
|
| gptkbp:headquartersLocation |
gptkb:Bridgewater,_New_Jersey,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Enzon, Inc.
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:Adagen
gptkb:PEG-Intron gptkb:DepoCyt gptkb:Oncaspar |
| gptkbp:stockSymbol |
gptkb:ENZN
|
| gptkbp:subsidiary |
gptkb:Enzon_Pharmaceuticals,_Inc.
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:website |
http://www.enzon.com/
|
| gptkbp:bfsParent |
gptkb:Enzon_Pharmaceuticals
|
| gptkbp:bfsLayer |
7
|